New-Onset Inflammatory Bowel Diseases Among Il-17 Inhibitors-Treated Patients: Results From The Case-Control Missil Study
Jean-Guillaume Letarouilly,Thao Pham,Adeline Pierache, Émilie Acquacalda,Beatrice Banneville,Sébastien Barbarot, Pauline Baudart,Élodie Bauer,Pascal Claudepierre,Arnaud Constantin,Emmanuelle Dernis,Renaud Felten,Philippe Gaudin,Céline Girard,Bruno Gombert,Philippe Goupille,Xavier Guennoc,Isabelle Henry-Desailly,Denis Jullien, Elena Karimova,Sylvain Lanot,Loïc Le Dantec,Tristan Pascart,Laurianne Plastaras,Nathalie Sultan, Xavier Truchet,Stephane Varin,Daniel Wendling,Louise Gaboriau,Delphine Staumont-Sallé,Laurent Peyrin-Biroulet,Rene-Marc Flipo ARTHRITIS & RHEUMATOLOGY（2020）
摘要
The incidence of new IBD was low and decreased from 2016 to 2019. The outcome was favourable in 24 out of 31 patients, but two patients died.
更多查看译文
关键词
IL 17 inhibitor,inflammatory bowel disease,psoriasis,psoriatic arthritis,real-world,secukinumab,spondyloarthritis
AI 理解论文
溯源树
样例
